Rocket Lab’s sales rose 62% from a year earlier, and its backlog grew 137%; new orders pushed its launch backlog beyond 100 missions. ARK’s buying shows investor interest, but Neutron remains in development, so its larger-market promise is not yet proven.
The added orders give Rocket Lab more scheduled work, and its reported sales rose as its backlog grew. That supports the company’s outlook. ARK’s buying shows investor interest, but it does not prove future results. Neutron could open a larger market, but its success has not yet been shown.
ARK funds sold about $3.95 million in Palantir shares, but the story gives no new information about Palantir’s business. The trades alone do not change the company’s outlook.
Follow Rocket Lab Corp. (RKLB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RKLB